Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barry Quart Insider Profile
4 Followers
Barry Quart, CEO, Director at Heron Therapeutics, holds 9.37K shares in Kiniksa Pharmaceuticals (Ticker: KNSA), holds 177.99K shares in Heron Therapeutics (Ticker: HRTX), holds 0.00 shares in Synageva (Ticker: GEVA).
Profitable Transactions
2 out of 7 Profitable Transactions
Average Return
-1.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Barry Quart holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 26, 2014 - Jun 26, 2015
Return:+154.70%
The most profitable trade made by Barry Quart
Barry Quart's Trading History
Heron Therapeutics
Jan 17, 2023
CEO, Director
Uninformative Buy
46.12K
$284.78K
Kiniksa Pharmaceuticals
Jun 07, 2024
Director
Uninformative Buy
85.36K
$188.77K
Synageva
Jun 24, 2014
―
Uninformative Sell
137.50K
―
List of latest transactions for each holding click on a transaction to see Barry Quart's performance on stock
You May Also Like
Barry Quart insider profile FAQ
What is the percentage of profitable transactions made by Barry Quart?
The percentage of profitable transactions made by Barry Quart is 29%.
What is the average return per transaction made by Barry Quart?
The average return per transaction made by Barry Quart is -1.80%.
What stocks does Barry Quart hold?
Barry Quart holds: HRTX, KNSA, GEVA stocks.
What was Barry Quart’s latest transaction?
Barry Quart latest transaction was an Uninformative Buy of $85.36K.
What was Barry Quart's most profitable transaction?
Barry Quart’s most profitable transaction was an Informative Buy of HRTX stock on June 26, 2014. The return on the trade was 154.70%.
What is Barry Quart's role in Heron Therapeutics?
Barry Quart's role in Heron Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.